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Background: Platelet-activating factor (PAF) is produced by most inflammatory cells and it is involved in
inflammatory and allergic reactions. We aimed to assess the anti-PAF effects of rupatadine and levocetirizine in the
upper airways.
Findings: Healthy volunteers (HV, N = 10) and seasonal allergic rhinitis (SAR, N = 10) asymptomatic patients were
treated out of the pollen season with either rupatadine 20 mg, levocetirizine 10 mg, or placebo once a day during
5 days prior to the PAF nasal challenge. Total 4-nasal symptom score (T4SS) and nasal patency (Vol2-5, by acoustic
rhinometry) were assessed from 0 to 240 minutes after a repeated PAF challenge. In SAR patients but not in HV,
both rupatadine and levocetirizine showed a trend to decrease PAF-induced T4SS from 60 to 120 minutes. Rupatadine
but not levocetirizine caused a significant reduction (p < 0.05) of T4SS area under the curve compared to placebo.
Rupatadine and levocetirizine caused no significant changes on nasal patency compared to placebo.
Conclusions: These results suggest that both rupatadine and levocetirizine showed a tendency decrease toward nasal
symptoms, but only rupatadine significally reduces the overall nasal symptoms (AUC) induced by PAF in SAR patients.
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Anti-PAF effects of rupatadine (20 mg) and levocetirizine
(10mg) in healthy volunteers (HV, N=10) and seasonal
allergic rhinitis (SAR, N=10) asymptomatic patients were
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article, unless otherwise stated. In SAR patients but not in HV, both rupatadine
and levocetirizine showed a trend to decrease
PAF-induced T4SS from 60 to 120 min in comparison
with placebo.
 Rupatadine but not levocetirizine caused a
significant reduction (p<0.05) of the overall nasal
symptoms (AUC from 30 to 240 min) induced by
PAF in SAR patients.
 No significant changes of nasal patency were
observed in comparison with placebo.Background
In addition to other inflammatory mediators, histamine
and PAF have a relevant participation in allergic inflamma-
tion. Therefore, blocking both PAF and histamine effectsral Ltd. This is an Open Access article distributed under the terms of the
ativecommons.org/licenses/by/2.0), which permits unrestricted use,
rovided the original work is properly cited. The Creative Commons Public
ns.org/publicdomain/zero/1.0/) applies to the data made available in this
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ing one [1]. Rupatadine has a dual anti inflammatory effect
by blocking both histamine H1 and PAF receptors [2]. As
a result, nasal provocation with PAF would allow the
evaluation of both clinical and inflammatory nasal response
after pharmacological treatment with anti-PAF drugs. In
previous investigations, PAF nasal provocation models
have shown contradictory results in assessing the
patophysiological mechanisms of allergic rhinitis due
in part to their lack of sensitivity and specificity [3-5].
Recently, we have investigated the role of PAF in nasal
symptoms by means of a human model of PAF nasal
challenge in both healthy volunteers (HV) and seasonal
allergic rhinitis (SAR) asymptomatic patients out of the
pollen season [6]. Long-lasting effects on nasal symptoms
were shown after PAF nasal challenge, mainly in nasal
obstruction, in both HV and SAR patients.
The aim of the present study was to assess and
compare the ability to block the nasal clinical response
induced by PAF, both in HV and SAR patients pretreated
with rupatadine or levocetirizine.
Methods
Study population
Twenty subjects, 10 HV and 10 SAR asymptomatic
patients, were recruited. All SAR patients had positive
prick test and serum specific IgE to grass or tree pollen,
along with compatible personal history of SAR. All subjects
were not allowed to use any medication (antihistamines
and/or corticosteroids) for 4 weeks prior to and during the
study. All SAR patients were asymptomatic at the inclusion
and the study was performed out of pollen season. TheFigure 1 Squeme and design of study. PAF: platelel-activating factor; Ac
(evaluated by Likert and visual analogic scales) FEV1: Forced expiratory volustudy was approved by the Ethics Committee of our
institution and informed consent was obtained from
all subjects participating before the study.
An Independent Ethics Committees from Hospital Clínic
i Provincial (Barcelona, Spain) reviewed and approved the
protocol and amendments, the subject’s informed consent
document, and related subject information and recruitment
materials before the start of the study.
Study design
A proof of concept randomized, double-blind crossover
study was designed. All subjects were randomized to
receive either rupatadine 20 mg, levocetirizine 10 mg,
or placebo once daily during 5 days prior the PAF
nasal challenge. A washout period of at least 15 days
was set between treatment periods.
First, the subjects were challenged with the drug solvent
(4% ethanol) thirty minutes before PAF administration
(0 minutes) to rule out unspecific nasal reactivity.
Three consecutive increasing doses of PAF (20, 40,
and 80 nmols, Sigma Aldrich, Madrid, Spain) were instilled
with a pipette (100 μl) into each nostril at 0, 30, and
60 minutes (Figure 1). PAF doses were selected based
on a pilot test and previously reported studies [3-5].
Clinical outcomes
Total 4-symptom score (T4SS) including rhinorrhea,
nasal congestion, nasal itching, and sneezing were scored
by the subjects by means of a visual analogue scale
(VAS, 0–100 mm) and a Likert scale (0 to 3 for each
symptom and from 0 to 12 for T4SS). Changes from
baseline (time 0) in T4SS were measured at 30, 60, 90,R: acoustic rhinometry; T4SS: total 4-symptoms score
me in 1 second.
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Additionally, the Area Under the Curve (AUC) of the
T4SS from 30 to 240 minutes was calculated and both
treatments were compared versus placebo.
Nasal patency was also evaluated by acoustic rhinometry
(AcR) (SER 2000; RhinoMetrics, Lynge, Denmark) in both
the right and left nasal cavities between the 2ndand 5thcm
(Vol2–5)[7].
Statistics
VAS and Lickert scale results were expressed as mean ± SD.
Nasal volume changes were expressed as the percentage
change from the nasal volume obtained with diluent
challenge. Data were compared using ANOVA test and
Student’s t-test for paired and unpaired data. The values
of p < 0.05 were considered statistically significant.
Results
No significant decreases of T4SS after PAF nasal challenge,
using either the Likert or VAS scales, were observed at anyFigure 2 Time-evolution on total nasal symptom score (T4SS) after re
evalueted by Likert scale: (A) in healthy subjects, and (B) in seasonaltime-point for the active treatments in comparison
with placebo, and in both HV and SAR patients.
Nevertheless, rupatadine caused a 73% decrease com-
pared to placebo of the T4SS (Likert scale) at 60 mi-
nutes after PAF in SAR patients. In comparison,
levocetirizine produced only a 23% inhibitory effect at
60 minutes (Figure 2). This trend shown by rupata-
dine was confirmed by the T4SS AUC. Rupatadine
showed a statistically significant 54% reduction compared
to placebo (AUC score: 262.5 versus 570, p < 0.05)
(Figure 3). The T4SS AUC of levocetirizine versus
placebo was non-statistically significant.
A progressive decrease in AcR was observed, never-
theless there were no differences between treatment
groups in the AUC time-course of nasal patency
(Vol2-5) after PAF challenge in both HV and SAR
patients.
Subjects participating in the study did not report any
adverse event related to PAF challenge or the treatment
with rupatadine, levocetirizine or placebo.peated platelet-activating factor (PAF) nasal challengue,
allergic rhinitis (SAR) patients.
Figure 3 Area under of curve of nasal symptoms (AUC) of T4SS time-course adjusted by baseline values at 30 min.
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In this proof of concept study, an increase of nasal
symptoms after nasal challenge with PAF was observed.
Rupatadine and levocetirizine showed a trend towards
decreasing nasal symptoms mainly at 60 minutes after
PAF challenge. Nevertheless, statistical differences were
not detected probably due to the small sample size and
also by the high variability of measurements observed.
Statistical significant differences were achieved after evalu-
ating overall time-course of symptoms (AUC). Rupatadine
but not levocetirizine significantly reduced AUC values in
SAR patients but not in healthy volunteers. In contrast,
the nasal patency assessed by AcR did not show any
significant changes between the three groups, even after
the comparison of AUC assessments.
The precise mechanism of the rupatadine anti-PAF
effect is not completely known, although it is thought to
be linked to its capacity of blocking the PAF receptors
[2,8-10]. PAF stimulates nasal mast cells [11] and has
the capability to attract and activate neutrophils and
eosinophils [12-14]. Thus, using this human nasal challenge
model we could demonstrate the activity of drugs
with the ability of blocking PAF receptors and reduce their
proinflammatory properties. Antihistamines have the ability
to stabilize the inactive form of the receptor of histamine
(inverse agonists), partially inhibiting paracrine/autocrine
effects of histamine. In this way, the second generation
antihistamines, reduce the intensity and duration of allergic
symptoms [15]. Levocetirizine and rupatadine are cap-
able of displaying antinflammatory effects through its
activities on the histamine receptors. Perhaps such
inhibition is not sufficient after a repeated nasal PAF
challengue and we could postulate that rupatadine
can provide additional antiinflamamatory effects by
means of its dual capacity of blocking histamine and
PAF receptors in comparison with levocetirizine [16,17].However, further studies with a higher sample size at
different rupatadine dose levels should be carried out
to confirm these findings.
In conclusion rupatadine and levocetirizine showed a
trend towards the reduction of nasal symptoms after
nasal challenge with PAF compared with placebo. A
statistically significant inhibitory effect was found only with
rupatadine when the AUC time-course of total nasal
symptoms was assessed in SAR patients. To our
knowlenge, this is the first evidence of PAF inhibitory
effects on human nasal airways using an antihistamine
drug with dual H1 and PAF receptor antagonist activities.
Nevertheless, further studies should be performed
with a major number of patients with a high and
unique dose of PAF challenge in order to reduce the
variability of data.
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